TCGA-C4-A0F0-01A-12R-A10U-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 1.938239159
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.680
- E2F_TARGETS+0.620
- MYC_TARGETS_V2+0.610
- G2M_CHECKPOINT+0.550
- OXIDATIVE_PHOSPHORYLATION+0.550
- MTORC1_SIGNALING+0.490
- PROTEIN_SECRETION+0.450
- UNFOLDED_PROTEIN_RESPONSE+0.420
- DNA_REPAIR+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.340
Top 10 suppressed
- APICAL_SURFACE-0.310
- KRAS_SIGNALING_DN-0.280
- MYOGENESIS-0.180
- NOTCH_SIGNALING-0.170
- BILE_ACID_METABOLISM-0.160
- ESTROGEN_RESPONSE_EARLY-0.140
- ESTROGEN_RESPONSE_LATE-0.050
- KRAS_SIGNALING_UP-0.040
- HEDGEHOG_SIGNALING-0.010
- WNT_BETA_CATENIN_SIGNALING+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD030391_D1.RNA-Seq | EPN | Supratentorial EPN | 0.909 |
| 2 | AFE5BFD1-AA9F-470A-A44F-341126F8057D | — | — | 0.894 |
| 3 | A07BA2E1-CCA0-4231-A391-B13383A2BCB9 | — | — | 0.893 |
| 4 | ECCC2F18-409F-41BA-B49F-95B23893B80B | — | — | 0.886 |
| 5 | A4821960-9921-4B07-98CE-C4FDCA15146D | — | — | 0.885 |
| 6 | 8F828A42-3E60-40C1-9E7D-428ABEA6C72F | — | — | 0.884 |
| 7 | AA605CB6-ABD9-4802-8784-75A18A74C87B | — | — | 0.881 |
| 8 | EBE58DF8-7300-4D3E-9672-A4E7ADF46113 | — | — | 0.880 |
| 9 | 261EAE5F-1B79-4324-84F6-1B0DDDA9B7B5 | — | — | 0.879 |
| 10 | 726D58A7-23E0-492A-B5CE-15DCB11B0C90 | — | — | 0.879 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.680 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.620 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.610 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.550 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.550 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.490 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.450 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.420 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.340 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.340 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.340 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.340 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.330 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.270 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.240 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |